Published data. Peer-reviewed results.
Two peer-reviewed publications. 64+ isolates tested. GLP-compliant safety studies. This is the research behind the EVOQ platform.
Peer-reviewed publications
The EVOQ platform is supported by published, externally validated research. These two peer-reviewed papers form the scientific foundation for EVQ-218.
Escaping the ESKAPE Antimicrobial Resistant Cycle with EVQ-218
Sakawa Sharif, A. et al. | Antibiotics 2026, 15(2), 224 | DOI: 10.3390/antibiotics15020224 Serial passage resistance testing across all six ESKAPE pathogens. No resistance detected after 30 passages under escalating selective pressure. DF-STEM/EDS imaging across 20+ isolates consistent with non-lytic, multi-target interaction.
View publicationEVQ-218: Characterization of High-Energy Nanoparticles that Measure up to NIST Standards
Kennon, B.S.; Niedermeyer, W.H. | ACS Omega 2024, 9(7), 7891–7903 | DOI: 10.1021/acsomega.3c07745 Physicochemical characterization of EVQ-218 via STEM, STEM-EELS, and DLS. NIST-validated size distribution. Bare metallic surface confirmed with no detectable oxidative layer.
View publication64+ isolates tested
In laboratory studies funded by the Cystic Fibrosis Foundation, EVQ-218 demonstrated antimicrobial activity across bacteria, fungi, and mycobacteria. Testing followed CLSI methods at Seattle Children's Research Institute.
30 serial passages. Zero resistance.
No resistance detected after serial passage across all six WHO-designated ESKAPE pathogens under the conditions tested. Zero cross-resistance observed relative to tobramycin and ciprofloxacin in three species tested.
Non-lytic. Multi-target.
DF-STEM/EDS imaging across 20+ isolates is consistent with intracellular, sulfur-associated engagement. EVQ-218 does not lyse cell walls. Mechanistically distinct from major antibiotic classes.
How the EVOQ platform compares
Conventional nanoscale synthesis is chemistry-first. Performance depends on coatings, capping agents, and ion release mechanisms. These approaches introduce batch variability, instability, and regulatory complexity.
The EVOQ model is structure-first. A patented high-energy laser ablation process produces uniform sphere metamaterials continuously. Shape, size, stability, and scalability are engineered at the point of production. No chemical additives. No post-synthetic refinement. No wet-chemistry waste streams.
Selected research and data
ESKAPE Serial Passage Study
Research paper. Resistance testing, cross-resistance, time-kill kinetics, DF-STEM/EDS imaging across six ESKAPE pathogens.
Read paperEVQ-218 NIST Characterization
Research paper. STEM, STEM-EELS, DLS profiling. NIST-validated size distribution. Bare metallic surface confirmation.
Read paperSilver in Healthcare
White paper. Historical evolution of silver in medicine. Antimicrobial mechanisms, wound care, medical devices, and regulatory context.
Read paperBattery Performance with EVQ-GA
White paper. Lead-acid and lithium-ion applications. Crystal chemistry optimization and impedance spectroscopy results.
Read paperGLP Dermal Sensitization
Test data. Buehler test per ISO 10993-10. GLP-compliant. Non-sensitizing under study conditions.
View dataMEM Elution Cytotoxicity
Test data. ISO 10993-5 and USP 87. GLP-compliant. Non-cytotoxic at tested dilutions.
View dataInterested in the data?
Request materials, access test reports, or connect with the research team.
Connect to our experts